The Miami Breast Cancer Conference was held from March 3-6, 2022. See below for some highlights from the meeting including updates about treatment options for different MBC subtypes.
Triple-Negative MBC
- OncLive: Chemoimmunotherapy for Metastatic TNBC
- MedPage Today: Precision Medicine in Metastatic TNBC
Triple-Negative and Hormone Receptor-Positive MBC
- OncLive: Eribulin Efficacy for MBC
HER2-Positive MBC
- MedPage Today: HER2+ MBC With Brain Metastases
Last Modified on April 6, 2022
